期刊文献+

床边检测N-末端脑利钠肽前体对心力衰竭的诊断价值 被引量:5

Diagnostic value of bedside immediate detecting plasma N terminal-pro brain natriuretic peptide in patients with congestive heart failure
下载PDF
导出
摘要 目的:探讨床边即时检测血浆N-末端脑利钠肽前体(NT-proBNP)浓度对充血性心力衰竭患者的诊断价值。方法:入选60例充血性心力衰竭(心衰组)及20例非心力衰竭患者(非心衰组)。根据NYHA心功能分级,心衰组又分为心功能Ⅱ、Ⅲ、Ⅳ级组;按左室射血分数(LVEF)将心衰组分为LVEF<40%组和≥40%组。测定所有研究对象的血浆NT-proBNP水平,LVEF和左室舒张末内径(LVEDd)。结果:(1)心衰组患者血浆NT-proBNP水平明显高于非心衰组患者[(2365±86)ng/L比(46±7)ng/L,P<0.01],心功能Ⅲ、Ⅳ级组NT-proBNP水平明显高于Ⅱ级组[(3069±96)ng/L、(3850±75)ng/L比(1056±82)ng/L,P<0.01];(2)LVEF<40%组的NT-proBNP显著高于≥40%组[(3456±71)ng/L比(585±35)ng/L,P<0.01];(3)如以400ng/L为正常参考值,NT-proBNP诊断心衰的敏感性为91.8%,特异性为93.6%;(4)心衰患者NT-proBNP水平与LVEDd呈正相关(r=0.736,P<0.01),与LVEF呈负相关(r=-0.68,P<0.05)。结论:床边即时检测血浆N-末端脑利钠肽前体对诊断心衰敏感而且特异,可作为心衰诊断的一个客观指标。 Objective: To study diagnostic value of bedside immediate detection of plasma N terminal--pro brain natri- uretic protein (NT--proBNP) in patients with congestive heart failure (CHF). Methods.. A total of 60 CHF patients (CHF group) and 20 non-CHF patients (non-CHF group) were enrolled. According to NYHA cardiac function classification, CHF group was divided into NYHA cardiac function class Ⅱ, Ⅲ and Ⅳ groups; according to left ventricular ejection fraction (LVEF), CHF group was divided into LVEF〈40% group and ILVEF40% group. Plasma level of NT-proBNP, LVEF and left ventricular end--diastolic dimension (LVEDd) were measured and compared among different groups. Results: (1) Plasma level of NT--proBNP in CHF group was significantly higher than that of non-CHF group [ (2365±86) ng/L vs. (46±7) ng/L, P〈0.01], and NT--proBNP levels in NYHA cardiac function class m and IV groups were significantly higher than that of NYHA cardiac function class Ⅱ group [ (3069 ±96) ng/L, (3850±75) ng/L vs. (1056±82) ng/L, P〈0.01]; (2) NT--proBNP level of LVEF〈40% group was significantly increased than that of LVEF±40% group [ (3456±71) ng/L vs. (585±35) ng/L, P〈0.01]; (3) When 400 ng/L was regard as normal reference value, sensitivity and specificity of NT--proBNP in diagnosing CHF were 91.8% and 93.6% respectively; (4) NT--proBNP level was positively correlated with LVEDd (r=0. 736, P 〈0.01), and negatively correlated with LVEF (r=-0.68, P〈0.05). Conclusion: Bedside immediate detection of plasma NTproBNP is sensitive and specific in diagnosing CHF and can be regard as an objective indicator for diagnosis of CHF.
出处 《心血管康复医学杂志》 CAS 2011年第6期575-577,共3页 Chinese Journal of Cardiovascular Rehabilitation Medicine
关键词 心力衰竭 充血性 利钠肽 心室功能 Heart failure, congestive Natriuretic peptide, brain~ Ventricular function, left
  • 相关文献

参考文献9

  • 1Kawai K, Hata K, Takaoka H, et al. Plasma brain natriuretic peptide as a novel therapeutic indicator in idiopathic dilated car- diomyopathy during beta-blocker therapy: a potential of hot- mone-guided treatment [J]. Am Heart J, 2001, 141 (6):925 -932.
  • 2Grzybowski J, Bilinska ZT, Janas J, et al. Plasma concentra tions of N-terminal atrial natriuretic peptide are raised in asymp tomatic relatives of dilated cardiomyopathy patients with left yen tricular enlargement [J] Heart, 2002, 88 (2): 191-192.
  • 3Suda K, Matsumura M, Matsumoto M. Clinical implication of plasma natriuretic peptides in children with ventricular septal de- fect [J]. Pediatr Int, 2003, 45 (3): 249-254.
  • 4Colan SD, Borow KM, Neumann A. Left ventricular end-sys- tolic wall stress-velocity of fiber shortening relation: a load-inde- pendent index of myocardial contractility [J]. J Am Coll Cardi oi, 1984, 4 (4): 715-724.
  • 5Bianciotti LG, de Bold AJ. Modulation of cardiac natriuretic peptide gene expression following endothelin type A receptor blockade in renovascular hypertension [J ]. Cardiovase Res,2001, 49 (4): 808-816.
  • 6邵乐文,韩阳,王战坤,孙坚.床边即时脑利钠肽检测对呼吸困难的诊断价值[J].中华心血管病杂志,2004,32(12):1123-1125. 被引量:30
  • 7迪丽努尔.塔吉,阿布力米提.米吉提.心功能不全患者血浆N-末端脑钠肽前体及血清尿酸浓度的相关性[J].心血管康复医学杂志,2010,19(2):125-127. 被引量:6
  • 8刘芳,王凤芝,张秀兰.肾上腺髓质素和脑利钠肽在慢性心力衰竭中的价值分析[J].中华心血管病杂志,2007,35(2):187-187. 被引量:2
  • 9李莉,李瑞杰,宋丽芬,王亚娟,葛利荣,王璐.运动康复改善老年慢性心衰患者心功能和生活质量的研究[J].心血管康复医学杂志,2006,15(4):315-318. 被引量:79

二级参考文献32

  • 1刘江生,张宏元,戴若竹,杨菊贤.老年急性心肌梗死合并心衰的康复[J].心血管康复医学杂志,2003,12(z1):579-581. 被引量:5
  • 2Marcelo E,Ochiai,Antonio CP,et al.Uric acid renal excretion and renal insufficiency in decompensated severe heart failure[J].The European Journal of Heart Failure,2005,7:468-474.
  • 3Alderman MH.Uric acid and cardiovascular risk[J].Our Opin Pharmacol,2002,2:126.
  • 4Clerico A,Recchia FA,Passino C.et al.Cardiacendocrine function is an essential component of the homeostatic regulation network:physiological and clinical implications.[J].Am J Physio l,2006,290(1):H 17-29.
  • 5ACC/AHA.2005 Guideline up date for the diagnosis and management of chronic heart failure in the adult[J].Circulation,2005,112 (4):154-235.
  • 6Dao Q,Krishmaswamy P,Kazanegra R,et al.Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent care setting[J].J Am Coll Caro1,2001,37:379-385.
  • 7Freedman DS,Williamson DF,Genler EW,et al.Relation of serum uric acid to motality and ischemic heart disease.The NILANESL epidemiologic follow-up study[J].Am J Epidemial,1995,141(7):637.
  • 8Culleton BF,Larson MG,Kannel WB,et al.Serum uric acid and risk for cardiovascular disease and death:the Framingham heart study[J].Ann Intern Med,1999,131(1):7213.
  • 9Puddu PE,Lanti M,Menotti A,et al.Serum uric acid for short-termprediction of cardiovascular disease incidence in the Gubbio population study[J].Acta Cardiol,2001,56(4):243-251.
  • 10Anker SD,Doehner W,Rauchhaus M,et al.Uric acid and survival chronic heart failure[J].Circulation,2003,107(4):1991-1997.

共引文献113

同被引文献71

  • 1高东奔,邵超华,梁淑兰,裴华,谭艳芬.NT-proBNP对陈旧性心肌梗死患者心力衰竭的诊断价值[J].安徽医学,2013,34(10):1459-1461. 被引量:2
  • 2Davenport C, et 81. Assessing the diagnostic test accuracy of nalriuretie peptides and ECG in the diagnosis of left ventricular systolic dys- function : a systematic review and meta - analysis [ J ]. The British Journal of General Practice, 2006, 56(522) : 48.
  • 3Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5. 1.0 [ updated March 2011 ]. The Coehrane Collaboration, 2011. Available from www. cochrane - handbook, org.
  • 4Devereanx PJ, Yang H, Yusut S, et M. Effects of extended -re- lease metoprolol succinate in patients undergoing non - cardiac surgery (POISE triM) : a randomized controlled triM[ J]. Lancet, 2008, 371(9627) : 1839.
  • 5de Denus S, Pharand C, Williamson DR. Brain natriuretic pep- tide in them anagement of heart failure The versatile neurohor- mone[J]. Chest, 2004, 125(2) : 652 -668.
  • 6Vesely DL. Which of the cardiac natriuretic peptides is most ef- fective for the treatment of congestive heat failure, renal failure and cancer[ J]. Clin Exp Pharmacol, 2006, 33(3) : 169 - 176.
  • 7O'Neill JO, Bott-Silverman CE, McRae AT 3rd, et al. B-type natriuretic peptide levels are not a surrogate marker for invasive hemodynamics during management of patients with severe heart failure[J].Am Heart J, 2005, 149(2): 363-369.
  • 8Groenning BA, Nilsson JC, Sondergaard L, et al. Evaluation of impaired left ventricular ejection fraction and increased dimensions by multiple neurohumoral plasma concentrations[J].Eur J Heart Fail, 2001, 3(6): 699-708.
  • 9Bettencourt P, Ferreira A, Dias P, et al. Predictors of prognosis in patients with stable mild to moderate heart failure[J].J Card Fail, 2000, 6(4): 306-313.
  • 10Maisel A, Mueller C, Adams K Jr, et al. State of the art: using natriuretie peptide levels in clinical practice[J].Eur J Heart Fail, 2008, 10(9): 824- 839.

引证文献5

二级引证文献37

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部